PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

Positive Lot-to-Lot Consistency Data Pave Way for Biologics License Application (BLA) Submission in 2015 December 8, 2014 PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved …

Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer

September 3, 2014 PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company. Mr. Meltz joins PaxVax from Biogen Idec, where …

The Most Influential People in Vaccines

Vaccine Nation presents the 50 most influential people in vaccines Download the Most Influential People in Vaccines to find out: Has Bill Gates lost his top spot? Who are the 25 new entries? Which disease field has produced the most influential experts Over the last two months we asked you to vote for who you believe are the three most influential …

Specialty Vaccine Company PaxVax Expands Global Commercial Team

August 7th, 2014 PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the expansion of its global commercial team with the appointments of Jonathan Klock as Vice President of Sales and Marketing, North America; Jeremy Gowler as Vice President of Global Marketing; and five U.S. National Account Directors. They join the European and U.S.-based commercial teams …

PaxVax Acquires the FDA-Approved Typhoid Vaccine Vivotif

July 28th, 2014 PaxVax Inc. a specialty vaccine company focused on travel and biodefense today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG as well as its manufacturing facility in Thörishaus near Bern Switzerland. Additionally PaxVax is acquiring marketing sales and distribution capabilities in select markets including the United States and certain other assets …

Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study

New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers’ Market and People in the Developing World June 1, 2014 PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced positive efficacy results from …

PaxVax Signs R&D Collaboration with UC San Diego to Develop a Vaccine to Prevent Herpes Simplex Virus Infections

June 10, 2014 PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. …

PaxVax Announces New Commercial Senior Leadership

February 03, 2014 PaxVax Inc., a speciality vaccine company focused on travellers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the expansion of its commercial leadership team, including appointments of: Linda Rubinstein as Chief Financial Officer; Piers Whitehead as Chief Corporate Development Officer; and Thomas Yonker as Vice President of Project Management. …